Baseline characteristics of the omega‐3 fatty acids (<scp>F</scp>ish oils) and <scp>A</scp>spirin in <scp>V</scp>ascular access <scp>OU</scp>tcomes in <scp>RE</scp>nal <scp>D</scp>isease (<scp>FAVOURED</scp>) study

Viecelli, Andrea K.; Pascoe, Elaine M.; Polkinghorne, Kevan R.; Hawley, Carmel M.; Paul‐Brent, Peta‐Anne; Badve, Sunil V.; Cass, Alan; Johnson, David W.; Kerr, Peter G.; Mori, Trevor A.; Scaria, Anish; Hooi, Lai Seong; Ong, Loke-Meng; Irish, Ashley

doi:10.1111/nep.12573

Cited by 11 publications

(7 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The design and results of the main outcomes of the FAVOURED study have been published[12–16] and the study protocol and statistical analysis plan are provided in Supporting Information S1 and S2 Files, respectively. FAVOURED was a prospective, double-blind, randomised controlled trial conducted in Australia, New Zealand, the United Kingdom and Malaysia involving 567 adults with stage 4 or 5 chronic kidney disease who were receiving or expected to receive HD within 12 months and scheduled for AVF surgery.…”

Section: Methodsmentioning

confidence: 99%

Fish oil and aspirin effects on arteriovenous fistula function: Secondary outcomes of the randomised omega-3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) trial

et al. 2019

Self Cite

View full text Add to dashboard Cite

BackgroundArteriovenous fistulas (AVF) for haemodialysis often experience early thrombosis and maturation failure requiring intervention and/or central venous catheter (CVC) placement. This secondary and exploratory analysis of the FAVOURED study determined whether omega-3 fatty acids (fish oils) or aspirin affected AVF usability, intervention rates and CVC requirements.MethodsIn 567 adult participants planned for AVF creation, all were randomised to fish oil (4g/d) or placebo, and 406 to aspirin (100mg/d) or placebo, starting one day pre-surgery and continued for three months. Outcomes evaluated within 12 months included AVF intervention rates, CVC exposure, late dialysis suitability failure, and times to primary patency loss, abandonment and successful cannulation.ResultsFinal analyses included 536 participants randomised to fish oil or placebo (mean age 55 years, 64% male, 45% diabetic) and 388 randomised to aspirin or placebo. Compared with placebo, fish oil reduced intervention rates (0.82 vs 1.14/1000 patient-days, incidence rate ratio [IRR] 0.72, 95% confidence interval [CI] 0.54–0.97), particularly interventions for acute thrombosis (0.09 vs 0.17/1000 patient-days, IRR 0.53, 95% CI 0.34–0.84). Aspirin significantly reduced rescue intervention rates (IRR 0.45, 95% CI 0.27–0.78). Neither agent significantly affected CVC exposure, late dialysis suitability failure or time to primary patency loss, AVF abandonment or successful cannulation.ConclusionAlthough fish oil and low-dose aspirin given for 3 months reduced intervention rates in newly created AVF, they had no significant effects on CVC exposure, AVF usability and time to primary patency loss or access abandonment. Reduction in access interventions benefits patients, reduces costs and warrants further study.

show abstract

Section: Methodsmentioning

confidence: 99%

Fish oil and aspirin effects on arteriovenous fistula function: Secondary outcomes of the randomised omega-3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) trial

et al. 2019

Self Cite

View full text Add to dashboard Cite

show abstract

“…As a result of the second amendment, the primary objective of FAVOURED was to assess the efficacy of fish oil supplementation on AVF failure at 12 months and the efficacy of aspirin was assessed as a secondary objective. Details of the original and amended study protocols have been published previously …”

Section: Methodsmentioning

confidence: 99%

Effect of Fish Oil Supplementation and Aspirin Use on Arteriovenous Fistula Failure in Patients Requiring Hemodialysis

et al. 2017

Self Cite

View full text Add to dashboard Cite

IMPORTANCEVascular access dysfunction is a leading cause of morbidity and mortality in patients requiring hemodialysis. Arteriovenous fistulae are preferred over synthetic grafts and central venous catheters due to superior long-term outcomes and lower health care costs, but increasing their use is limited by early thrombosis and maturation failure. ω-3 Polyunsaturated fatty acids (fish oils) have pleiotropic effects on vascular biology and inflammation and aspirin impairs platelet aggregation, which may reduce access failure. OBJECTIVE To determine whether fish oil supplementation (primary objective) or aspirin use (secondary objective) is effective in reducing arteriovenous fistula failure. DESIGN, SETTING, AND PARTICIPANTSThe Omega-3 Fatty Acids (Fish Oils) and Aspirin in Vascular Access Outcomes in Renal Disease (FAVOURED) study was a randomized, double-blind, controlled clinical trial that recruited participants with stage 4 or 5 chronic kidney disease from 2008 to 2014 at 35 dialysis centers in Australia, Malaysia, New Zealand, and the United Kingdom. Participants were observed for 12 months after arteriovenous fistula creation.INTERVENTIONS Participants were randomly allocated to receive fish oil (4 g/d) or matching placebo. A subset (n = 406) was also randomized to receive aspirin (100 mg/d) or matching placebo. Treatment started 1 day prior to surgery and continued for 12 weeks. MAIN OUTCOMES AND MEASURESThe primary outcome was fistula failure, a composite of fistula thrombosis and/or abandonment and/or cannulation failure, at 12 months. Secondary outcomes included the individual components of the primary outcome. RESULTS Of 1415 eligible participants, 567 were randomized (359 [63%] male, 298 [53%] white, 264 [47%] with diabetes; mean [SD] age, 54.8 [14.3] y). The same proportion of fistula failures occurred in the fish oil and placebo arms (128 of 270 [47%] vs 125 of 266 [47%]; relative risk [RR] adjusted for aspirin use, 1.03; 95% CI, 0.86-1.23; P = .78). Fish oil did not reduce fistula thrombosis (60 [22%] vs 61 [23%]; RR, 0.98; 95% CI, 0.72-1.34; P = .90), abandonment (51 [19%] vs 58 [22%]; RR, 0.87; 95% CI, 0.62-1.22; P = .43), or cannulation failure (108 [40%] vs 104 [39%]; RR, 1.03; 95% CI, 0.83-1.26; P = .81). The risk of fistula failure was similar between the aspirin and placebo arms (87 of 194 [45%] vs 83 of 194 [43%]; RR, 1.05; 95% CI, 0.84-1.31; P = .68). CONCLUSIONS AND RELEVANCE Neither fish oil supplementation nor aspirin use reduced failure of new arteriovenous fistulae within 12 months of surgery.

show abstract

“…Ethics approval for the FAVOURED trial was obtained by each local Institutional Ethics Committee for participating sites before commencement. The study methodology, 18 baseline characteristics 19 and main trial findings have been reported elsewhere 17 . This sub‐study involved participants from the Australian, New Zealand and Malaysian sites, and explored the dietary and lifestyle habits of study participants as listed in the original trial methods 18 and study protocol.…”

Section: Methodsmentioning

confidence: 99%

Dietary habits in Australian, New Zealand and Malaysian patients with end stage kidney failure: A pre‐specified cross‐sectional study of the FAVOURED trial participants

Conley

Barden

Viecelli

et al. 2022

J Human Nutrition Diet

Self Cite

View full text Add to dashboard Cite

Background: Dietary management plays an important role in patients with kidney failure. Current dietary habits of Australians and New Zealanders (ANZ) and Malaysians with chronic kidney disease (CKD Stage 4-5) have not been adequately investigated. We report the dietary habits of people with advanced CKD and their adherence to country-specific dietary guidelines. Methods: Participants with CKD Stage 4-5, enrolled in the Omega-3 Fatty Acids (Fish oils) and Aspirin in Vascular access Outcomes in Renal Disease (FAVOURED) trial, completed a lifestyle questionnaire at baseline on their dietary intake. Results: Of 567 participants, 538 (ANZ, n = 386; Malaysian, n = 152; mean ± SD age 54.8 ± 14.3 years, 64% male) completed the questionnaire. Dietary fruit and vegetable intakes were higher in ANZ participants; 49% (n = 189)

show abstract

Baseline characteristics of the omega‐3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study

Cited by 11 publications

References 21 publications

Fish oil and aspirin effects on arteriovenous fistula function: Secondary outcomes of the randomised omega-3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) trial

Fish oil and aspirin effects on arteriovenous fistula function: Secondary outcomes of the randomised omega-3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) trial

Effect of Fish Oil Supplementation and Aspirin Use on Arteriovenous Fistula Failure in Patients Requiring Hemodialysis

Dietary habits in Australian, New Zealand and Malaysian patients with end stage kidney failure: A pre‐specified cross‐sectional study of the FAVOURED trial participants

Contact Info

Product

Resources

About